Localized Prostate Cancer | ICHOM – International Consortium for Health Outcomes Measurement

Localized Prostate Cancer

Localized Prostate Cancer

Localized Prostate Cancer

The ICHOM Standard Set for Localized Prostate Cancer was published in European Urology.


The ICHOM Standard Set for Localized Prostate Cancer is the result of hard work by a group of leading physicians, measurement experts and patients. It is our recommendation of the outcomes that matter most to patients with Localized Prostate Cancer. We urge all providers around the world to start measuring these outcomes to better understand how to improve the lives of their patients.

Localized Prostate Cancer

1 Recorded via the Clavien-Dindo-Classification
2 Recorded via the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
3 Recommend to track via the Expanded Prostate Cancer Index Composite (EPIC)-26

© 2015 ICHOM. All rights reserved. When using this set of outcomes, or quoting therefrom, in any way, we solely require that you always make a reference to ICHOM as the source so that this organization can continue its work to define more standard outcome sets.

View testimonials from our Working Group members

Team that developed this standard


Kim Moretti | South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC); The Queen Elizabeth Hospital
Mark Frydenberg | Prostate Cancer Registry of Victoria; Monash University. South Australien Prostate Cancer Clinical Outcomes
Ian Roos* | Melbourne Graduate School of Education, University of Melbourne; Cancer Action Victoria


Hartwig Huland | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Markus Graefen | Martini-Klinik at University Medical Center Hamburg-Eppendorf
Michael Froehner | University Hospital Carl Gustav Carus, Technical University of Dresden
Thomas Wiegel | University Hospital Ulm
Günter Feick* | Bundesverband Prostatakrebs Selbsthilfe (BPS); Europa UOMO


Frank Sullivan | Galway University Hospital; Prostate Cancer Institute at NUI Galway
John Fitzpatrick | Irish Cancer Society


Jacob Ramon | Sheba Medical Center


Alberto Briganti | Vita-Salute San Raffaele University Hospital


Chris Bangma | Erasmus Medical Center


Anna Bill-Axelson | Uppsala University Hospital; National Prostate Cancer Register (NPCR) of Sweden

United Kingdom

Adam Glaser | Leeds Teaching Hospitals NHS Trust
James Catto | Academic Urology Unit and Academic Unit of Molecular Oncology, CR-UK/YCR Sheffield Cancer Research Centre

United States

Steven Jay Frank | MD Anderson Cancer Center
David Swanson | MD Anderson Cancer Center
Andrew Vickers | Memorial Sloan-Kettering Cancer Center
Adam Kibel | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Anthony D’Amico | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Neil Martin | Dana-Farber Cancer Institute; Brigham and Women's Hospital
Michael Blute | Massachusetts General Hospital
Howard Sandler | Cedars-Sinai Medical Center
Ronald Chen | University of North Carolina Lineberger Comprehensive Cancer Center
Nancy Mendenhall | University of Florida Proton Therapy Institute
Daniel Hamstra | University of Michigan Health System
Ashutosh Tewari | Icahn School of Medicine at Mount Sinai Hospital

*Patient representative

Receive Updates

Reference Guide

A complete overview of the ICHOM Standard Set, including definitions for each measure and selected PROM instruments, time points for collection, and associated risk factors is available here:


Version 2.0.5: April 7th, 2017

3,1 MB

Get the Flyer

2,1 MB

Get the Database

40 KB

How to measure?

Interested in measuring the ICHOM Standard Set? Learn how to measure.